Broberger U, Graff-Lonnevig V, Lilja G, Rylander E
Clin Allergy. 1986 Mar;16(2):119-27. doi: 10.1111/j.1365-2222.1986.tb00755.x.
Twenty-nine children with an average age of 10.5 years were studied with respect to the protective effect of ketotifen on pollen-induced bronchial asthma. All of them were sensitive to deciduous tree pollen, the diagnosis being verified by bronchial challenge. The children were stratified in matched pairs and randomly allocated to two treatment groups, placebo or ketotifen 1 mg twice daily. The study was double-blind and was performed during the whole of the deciduous tree pollen season. Daily pollen counts were made, allergic symptoms were noted, additional medication was given and the expiratory pulmonary flow was recorded. During the birch pollen peak the ketotifen group showed significantly fewer, and less severe asthma and rhinoconjunctivitis than the placebo group. The anti-asthmatic medication was also used significantly less than in the placebo group. Ketotifen appeared to have good protective properties in the treatment of pollen-induced asthma and rhinoconjunctivitis.
对29名平均年龄为10.5岁的儿童进行了关于酮替芬对花粉诱发的支气管哮喘保护作用的研究。他们所有人都对落叶树花粉敏感，支气管激发试验证实了诊断。这些儿童被配对分层并随机分为两个治疗组，即安慰剂组或每日两次服用1毫克酮替芬组。该研究为双盲研究，在整个落叶树花粉季节进行。每天进行花粉计数，记录过敏症状，给予额外药物治疗并记录呼气肺流量。在桦树花粉高峰期，酮替芬组的哮喘和鼻结膜炎症状明显比安慰剂组少且轻。抗哮喘药物的使用也明显少于安慰剂组。酮替芬在治疗花粉诱发的哮喘和鼻结膜炎方面似乎具有良好的保护作用。
